Generic opioids gain momentum against brand-name drugmakers

Brand-name drugmakers behind the narcotic painkillers Opana and OxyContin are losing their bid to prevent the introduction of the drugs' cheaper generic versions. Most of the bills that would prohibit pharmacists from dispensing generics that aren't tamper-resistant when a tamper-resistant form is prescribed have failed partly because they are opposed by pharmacists. "We understand the value in developing appropriate abuse-resistant technology and we want to find a way of incentivizing that," FDA official Dr. Douglas Throckmorton said. "But we also understand the value of generics for patients."

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief: